New IBD drug candidate INT-210 begins first human safety tests
Knowledge-focused
Completed
This Phase 1 trial tested the safety and tolerability of INT-210 capsules in 86 healthy adults aged 18-45. Participants received single or multiple doses of the drug or a placebo, and researchers monitored side effects and how the drug moves through the body. The study also looke…
Phase: PHASE1 • Sponsor: Innatus Therapeutics (Shanghai) Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC